Recent Updates
Recently added Catalysts
ELDN Positive Sentiment

Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial

Thursday, June 25, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Natera and Eledon have formed a strategic partnership to utilize the Prospera monitoring assay in Eledon's upcoming Phase 3 trial of tegoprubart for kidney transplantation. This collaboration aims to enhance donor-derived cell-free DNA monitoring. The trial is anticipated to begin in late 2026, marking a significant step in kidney transplant research.
Price reaction · baseline $3.96 (2026-06-24 close) · hit pre-market · 3 other ELDN headline(s) in the window, move may be shared
day 0 close · peak
-7.8%
day 1
-4.5%
day 3
-0.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Strategic partnership enhances monitoring capabilities.
  • Prospera selected as exclusive monitoring assay.
  • Phase 3 trial expected to advance kidney transplantation research.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+90%
120-day peak, hindsight
Typical move
6.5%
average across 7 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
AT-1501
Phase 2 · Kidney Transplant Rejection

Full Press Release Details

Prospera selected as exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay for use in Eledon’s planned Phase 3 trial of tegoprubart in kidney transplantation, expected to initiate in late 2026 AUSTIN, Texas & IRVINE, Calif. --(BUSINESS WIRE)--Jun. 25, 2026-- Natera, Inc.

Frequently Asked Questions

What is the purpose of the Eledon and Natera partnership?

The partnership aims to utilize the Prospera assay for monitoring in Eledon's Phase 3 kidney transplant trial.

When is the Phase 3 trial expected to start?

The Phase 3 trial is expected to initiate in late 2026.

What is Prospera used for in this context?

Prospera is used as an exclusive donor-derived cell-free DNA monitoring assay.

What is tegoprubart?

Tegoprubart is the treatment being evaluated in the planned Phase 3 kidney transplantation trial.

ShareAdd on Google
Tags: ELDN Viatris Investor Conferences Healthcare Eledon Natera Prospera kidney transplantation Phase 3 trial
Last updated: Jun 25, 2026

Biotech snapshot

Cash runway
$89M liquidity · $8M/mo burn
~11 mo
Medium dilution risk
Lead asset
AT-1501Phase 2
Kidney Transplant Rejection →

Catalyst track record

+90%
best trade around ELDN's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for ELDN.

See every catalyst's timing & PoA →